Company ProfilePremium

Aarti Industries

Company Profile Analysis

Tickers: AARTIIND.NS, 524208.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Aarti Industries - Company showcase

Year Founded & Workforce

1984

6,000 Employees

Aarti Industries logo

Aarti Industries Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Aarti Industries Overview

Aarti Industries is India's dominant benzene-and-toluene-derivatives platform and, on the company's own account, a global top-tier producer in the nitro chloro benzene (NCB) value chain. It is not a diversified conglomerate but a deep, vertically integrated intermediates specialist: it takes commodity aromatic feedstocks — benzene, toluene, chlorine, sulphur, aniline — and converts them, through chlorination, nitration, hydrogenation, ammonolysis, ethylation, methylation and fluorination, into more than 100 downstream intermediates supplied to roughly 1,100 customers in 60 countries. Its economics are those of a cost-advantaged process manufacturer with scale barriers, not a high-margin formulator: FY2026 EBITDA margin was 14.1% and return on capital employed roughly 7%. The strategic question facing the company is whether a five-year, capital-intensive expansion cycle — Zone IV at Jhagadia, multi-purpose plants, fuel-additive capacity, and two joint ventures — converts into the ₹1,800–2,200 Cr EBITDA and >15% ROCE management has guided for FY2028, or merely into a larger, lower-returning asset base.


What the company actually does

Aarti Industries manufactures and sells speciality and intermediate chemicals derived principally from two aromatic feedstocks: benzene and toluene. The business is best understood not as a portfolio of products but as a set of interlocking value chains, each anchored on a core chemistry capability and extended downstream through successive reaction steps that add margin and lock in customers.

The company's key disclosed value chains are:

Nitro Chloro Benzenes (NCB): the historical core and the chain in which management claims global leadership. Products include ortho- and para-nitro chlorobenzene (ONCB/PNCB) and their downstream derivatives, feeding dyes, pigments, agrochemicals and pharmaceutical intermediates.

Di-Chloro Benzenes (DCB): including para-dichlorobenzene (PDCB), a significant US export line, used in polymer (PPS resin) and deodorant/insecticide applications.

Phenylenediamines (PDA): including MPDA, used in polymer additives and rubber chemicals. This chain has been the company's most persistently underperforming line, pressured by Chinese competition and soft US demand.

Nitro Toluene (NT) derivatives: including ethylation and methylation products. Mono Methyl Aniline (MMA) — an octane-booster fuel additive — sits in this chain and has become the company's single largest volume growth engine.

Sulphuric acid and downstream: including oleum and acid-chain derivatives; a captive-integration and merchant business.

Hydrogenation, fluorination and speciality chemistries: cross-cutting capabilities feeding pharma and agro intermediates.

Business model and revenue model

The revenue model is almost entirely product sales of manufactured chemical intermediates. There is no subscription revenue, no software, no royalty stream of material size. Three commercial structures coexist:

  1. Spot and short-tenor merchant sales — the majority of volume, priced against feedstock and freight, with pass-through lags of roughly one quarter. This is where margin volatility originates.

  2. Long-term supply contracts — multi-year, volume-committed agreements with global agrochemical and chemical majors. Two are currently material: a US$150 million multi-year agrochemical intermediate contract running to 31 March 2030, signed 12 March 2026 and requiring no incremental capex; and an exclusive long-term supply agreement with a leading global chemical company, materially amended in 2026 to add a ₹200–250 Cr backward-integration investment at Dahej SEZ, converting the relationship into an end-to-end manufacturing model over a remaining 15-year term. India Ratings has cited these contracts as a core support to AIL's revenue visibility.

  3. CDMO / custom synthesis and contract manufacturing (CRAMS) — marketed as a growth avenue, executed through the pilot plant and the new Multi-Purpose Plant (MPP) at Jhagadia. Current CDMO revenue contribution is not separately disclosed.

Value chain position

AIL sits in the middle of the chemical value chain: downstream of petrochemical crackers and chlor-alkali producers, upstream of formulators (agrochemical companies, pharmaceutical API makers, dye houses, polymer compounders, fuel blenders). This position confers two structural properties. First, the company is a price-taker on inputs and a price-setter only where it holds technical or scale monopoly — which is why crude-linked benzene and toluene inflation compresses margin before it can be passed through. Second, because switching an approved intermediate requires customer requalification, incumbency is sticky: customer qualification cycles are a moat, and the company's repeated references to "customer qualification phase" for PEDA and MPP products reflect this.

Customer types and end-markets

End-use applicationShare of revenue Q1 FY2027 (%)
Energy and additives (fuel additives / octane boosters)38
Agrochemicals and fertilizers18
Dyes, pigments and printing inks15
Pharmaceuticals14
Polymer and additives11
Other / unallocated (residual)4

Customers are industrial B2B buyers: global agrochemical innovators, pharmaceutical and API manufacturers, dye and pigment houses, polymer and additive producers, and fuel blenders/refiners. The company reports 1,100+ customers across 60 countries, with exports at 59% of revenue in Q1 FY2027.

End-market exposure (Q1 FY2027, unaudited, from investor presentation):

The company's own characterisation vs. an independent view

The company describes itself as "a leading global speciality chemicals company" with "40 years of chemistry expertise," combining "process chemistry expertise with scale-up engineering to deliver advanced intermediates."

Independent characterisation: the "speciality" label overstates the margin structure. A genuine speciality chemicals business earns 20–30% EBITDA margins and high-teens ROCE through formulation IP and application service. Aarti earns 14% EBITDA margins and ~7% ROCE, with margins that move with benzene, toluene, freight and Chinese export pricing. What Aarti actually possesses is a scale-and-integration cost position in a set of mid-value aromatic intermediates, with genuine global scale in NCB and a genuinely differentiated position in octane-booster fuel additives. That is a valuable, defensible business — but it is closer to an integrated intermediates franchise than to a speciality formulator, and it should be valued and stress-tested accordingly.

Strategy

Stated strategy

Management's articulated strategy rests on three declared core strengths — sustainable manufacturing, newer development capabilities, and customer relationships — deployed across four growth avenues:

  1. MPP and Zone IV commercialisation — enabling rapid development, qualification and commercialisation of new advanced chemistries, plus chlorotoluene commissioning opening agrochemical and pharmaceutical opportunities.

  2. Entry into adjacent markets and new platforms — explicitly naming advanced materials, battery materials, defence, and coatings.

  3. Strategic alliances and CDMO services — "promoting India as a manufacturing destination of choice" and partnering with customers for new India-based investments.

  4. Sustainable manufacturing and chemical recycling — the Re Aarti pyrolysis platform.

The corporate philosophy is framed around the values of Care, Integrity and Excellence, and the ambition of being a "Global Partner of Choice."

Medium-term financial targets

TargetValueTimeframe
EBITDA₹1,800–2,200 CrFY2028
Debt / EBITDABelow 2.5xOngoing
Return on capital employedAbove 15%Ongoing
Capital expenditure FY2027₹700–800 CrFY2027
EBITDA growth driverContribution (INR Cr)Status
Cost optimisation150–200Largely completed
Volume and margin ramp-up350–550On track as planned
Capex-led growth (all commissioning FY2027)300–450Commissioning in phases; Zone IV delayed 2 quarters
Total incremental800–1,200—

Assessment of the EBITDA target. From the FY2026 base of ₹1,172 Cr, the midpoint target of ₹2,000 Cr requires 70% EBITDA growth in two years. Management has published a bridge:

₹1,172 Cr + ₹800–1,200 Cr = ₹1,972–2,372 Cr, bracketing the ₹1,800–2,200 Cr target. The bridge is arithmetically coherent. Its weakest leg is the ₹300–450 Cr capex-led component, which depends entirely on assets that have already slipped: Zone IV by two quarters, chlorotoluene by 3–6 months, Re Aarti by three months.

Assessment of the leverage and ROCE targets. Net debt/EBITDA at roughly 3.7x (FY2026 derived) versus a <2.5x ceiling, and ROCE at ~7% versus a >15% target, mean both targets are currently breached by wide margins. Achieving ₹2,000 Cr EBITDA without further debt growth would bring net debt/EBITDA to roughly 2.1x — so the leverage target is achievable if and only if the EBITDA target is achieved. The two are not independent commitments; they are the same bet stated twice.

Announced strategic initiatives, last 24 months

InitiativeDateDetail
MMA capacity expansion, phase 1FY2026200 kTPA → 290 kTPA
MMA capacity expansion, phase 2July 2026290 kTPA → 360 kTPA, completed
DCB debottleneckingUnderway120 kTPA → 140 kTPA
Zone IV, JhagadiaFY2026–FY2028₹1,600–1,800 Cr total capex; MPP and chlorotoluene blocks using indigenous technology; phased commissioning FY2027, ramp-up FY2028–29
US$150m agrochemical supply contract12 March 2026To 31 March 2030; no incremental capex required
Backward-integration amendment, global chemical majorQ4 FY2026₹200–250 Cr at Dahej SEZ; end-to-end model over remaining 15-year term
Augene (Superform JV)Commissioning Q2 FY2027DCA downstream; profit contribution expected within 2–4 quarters of commissioning
Re AartiCommissioning H2 FY2027Chemical recycling of plastics; pyrolysis oil customer engagement underway
PEDAIn qualificationDEA downstream integration
Fuel-additive product pipelineFY2027–FY20285–10 new products by end-FY2027; 25–30 by FY2028
China subsidiaryPlannedSourcing and market expansion
Digital and GenAI programmeQ1 FY202740+ GenAI use cases executed in the quarter; in-house digital analytics capability
Cost savings driveFY2026–FY2027All value chains; product yield and energy efficiency; 70% of identified initiatives implemented
Renewable power phase 2 / back-pressure turbines / waste energyFY2026–FY2027Components of the ₹150–200 Cr cost-optimisation bucket

Products & Services

The company markets over 100 products. Public disclosure is organised by value chain rather than by SKU, and per-product pricing is not disclosed for any line (all products are sold on negotiated B2B terms). The catalogue below is assembled at the level at which the company actually discloses.

Nitro Chloro Benzene (NCB) chain

AttributeDetail
Core productsOrtho-nitro chlorobenzene (ONCB), para-nitro chlorobenzene (PNCB), and downstream derivatives
ChemistryChlorination followed by nitration of benzene; downstream hydrogenation and ammonolysis
Target customersDye and pigment houses; agrochemical formulators; pharmaceutical intermediate manufacturers
Competitive positionCompany claims global leadership in the NCB-based speciality chemicals segment; Crisil cites "market leadership" as a core rating strength
UtilisationAbove 85% across FY2025, FY2026 and Q1 FY2027
Current driverChina's April 2026 withdrawal of the export VAT rebate on major NCB-chain products lifted global pricing 7–10%
Pricing modelNegotiated B2B; feedstock-linked

Di-Chloro Benzene (DCB) chain — including PDCB

AttributeDetail
Core productsOrtho-dichlorobenzene (ODCB), para-dichlorobenzene (PDCB), downstream derivatives
Capacity120 kTPA, being debottlenecked to 140 kTPA
Target customersPolymer producers (PPS resin chain), agrochemical and household-products manufacturers
GeographyPDCB accounts for 15–20% of total US exports by value
Current driverStrong PDCB and downstream demand supports the debottleneck; US tariff reduction from >50% to ~18%+ improves landed economics for all suppliers

Nitro Toluene (NT), Ethylation and Methylation chain — including MMA fuel additives

AttributeDetail
Flagship productMono Methyl Aniline (MMA) — octane-booster fuel additive
Capacity trajectory200 kTPA → 290 kTPA (FY2026) → 360 kTPA (completed July 2026)
Related productsMono-ethyl aniline (MEA), di-ethyl aniline (DEA), and the downstream PEDA integration product
Target customersFuel blenders and refiners globally; 94% export-oriented
ContributionMMA represents 50–60% of total US exports by value; the energy application is the single largest revenue block at 38%
PipelineManagement targets 5–10 new fuel-additive products by end-FY2027 and 25–30 by FY2028
UtilisationHigh throughout FY2025–Q1 FY2027

Phenylenediamines (PDA) chain

AttributeDetail
Core productsPhenylenediamines including MPDA
Target customersPolymer additive and rubber chemical manufacturers
StatusThe portfolio's weakest chain: utilisation in "red" through FY2025–FY2026, improving to "yellow" in Q1 FY2027. Subdued US demand and heavy Chinese competition; MPDA specifically continues to underperform
Growth initiativeA PDA project is progressing through market-seeding and is expected to commercialise near-term

Sulphuric acid and downstream

AttributeDetail
Core productsSulphuric acid, oleum and downstream acid-chain derivatives
RoleDual — captive integration into nitration chemistry, and merchant sales
Strategic noteThe acid, DCB and NCB value chain expansion is one of three pillars of the ₹350–550 Cr volume-and-margin EBITDA ramp target

Fluorination and speciality chemistries

AttributeDetail
ApplicationPharmaceutical and agrochemical intermediates
StatusFluoro product margins under pressure from high competitive intensity (Q1 FY2027 management commentary)
Growth role"Fluorination and speciality chemicals growth" is an explicit component of the volume-and-margin EBITDA bridge

New and pipeline platforms

PlatformDescriptionStatus / timing
Multi-Purpose Plant (MPP), Jhagadia Zone IVModular reactor trains, digital automation, high-mix campaign flexibility. Operating envelope −20°C to +200°C, up to 25 bar; materials of construction include SS, MSGL, Hastelloy and PFA; automated control for batch-to-batch reproducibilityProducts in customer qualification; plants expected operational Q2 FY2027
Pilot Plant & Technology Innovation Centre, Zone IV50–1,000 L reactors, advanced process control, DoE and kinetic modelling, impurity mapping, APSRA process-safety risk assessment, dedicated HPLC/GC/spectroscopy labCommissioning to fuel new product development in FY2027
Chlorotoluene value chainNew chain using indigenous technology; opens agrochemical and pharmaceutical opportunitiesDelayed 3–6 months; phased commissioning through FY2027
PEDADownstream integration of the DEA/ethylation chainIn customer qualification phase
CoralNew agrochemical-linked productMarket development underway ahead of plant commissioning
Calcium chloride (CaCl2), Zone IVChemical charging commencedZone IV block, FY2026–27
"Augene" (Superform JV)DCA downstream joint ventureNear-commissioning; commercialisation Q2 FY2027; expected to contribute meaningfully to profit within 2–4 quarters of commissioning
"Re Aarti"Chemical recycling of plastics (pyrolysis oil)Critical equipment delivered, on-ground execution underway; commissioning pushed to H2 FY2027 on labour constraints
CDMO / CRAMS servicesContract development and manufacturing leveraging pilot-to-MPP scale-up ecosystemMarketed; revenue contribution not separately disclosed
Aarti MahasuperBranded offering listed on the company website—

Financial Narrative

All figures consolidated, ₹ crore unless stated, net of GST. FY2022 is not like-for-like (see Data-Integrity Preface).

Income statement

Note: diluted EPS is materially identical to basic (Q1 FY2027 basic ₹4.27 vs diluted ₹4.26). Dividend per share for FY2026 was ₹1.00 (20% on ₹5 face value), recommended by the Board on 4 May 2026.

Margin structure

Gross profit is not separately disclosed in the company's summary reporting format; Indian schedule-III presentation aggregates cost of materials, purchases and inventory change. Gross margin is therefore marked not publicly disclosed rather than estimated.

Revenue CAGR

The FY2023–FY2026 three-year CAGR of 7.8% is the only clean growth number in this table; everything anchored on FY2022 is contaminated by the demerger and the contract-termination compensation.

Balance sheet

Net debt is disclosed only as a ratio: net debt-to-equity was 0.66x at Q1 FY2026, 0.72x at 31 March 2026, and 0.80x at Q1 FY2027. Applying 0.72x to FY2026 equity implies net debt of approximately ₹4,288 Cr and net debt/EBITDA of roughly 3.7x — materially above management's stated <2.5x ceiling. This is the single most important number in the dossier and it is derived, not disclosed.

Cash flow

Capex figures: FY2025 guided at ₹1,300–1,500 Cr (revised down from ₹1,500–1,800 Cr); FY2026 actual approximately ₹1,125 Cr (raised in-year from ₹1,000 Cr to ~₹1,100 Cr for MMA and PEDA acceleration); FY2027 guided at ₹700–800 Cr, of which ₹180 Cr was deployed in Q1 FY2027.

Dividends paid and buybacks: dividend outflow is small — FY2026 payout was 9% of PAT (₹1.00/share on ~36.3 crore shares ≈ ₹36 Cr). No share buyback authorisation was identified in the period reviewed.

Ratio analysis

Additional ratios disclosed by the company at quarter-end:

Current ratio below 1.0x is worth flagging: at 0.82x, current liabilities exceed current assets, reflecting heavy reliance on short-term working-capital facilities and a payables-stretch strategy (payable days rose from 24 in FY2023 to 126 in FY2026).

Commentary: trends, inflections and drivers

The FY2022 cliff. Reported operating margin collapsed from 28.3% to 16.5% between FY2022 and FY2023. This is not primarily an operating deterioration — it is the combined effect of the pharma demerger and the non-recurrence of contract-termination compensation. Analysts who model a "margin recovery to FY2022 levels" are modelling a return to an accounting artefact.

The FY2023–FY2025 compression. Across these three years, revenue grew 9.8% cumulatively while net profit fell 39%. The mechanism is fully visible in the table: depreciation rose from ₹310 Cr to ₹434 Cr (+40%) and finance cost from ₹168 Cr to ₹275 Cr (+64%), as a capex programme funded substantially by debt landed on the P&L before the associated revenue arrived. EBITDA margin drifted from 16.5% to 13.8% under Chinese oversupply, weak agrochemical demand and inventory destocking across the global chemical chain. ROCE fell from 10% to 6% — the central indictment of the strategy to date.

The FY2026 inflection. FY2026 was the first year of genuine improvement: revenue +14% net, EBITDA +17% (₹1,000 Cr to ₹1,167 Cr), PAT +27%. Margin expanded modestly (13.8% to 14.1%), and Q4 FY2026 EBITDA margin reached 15.56% against 13.75% a year earlier. Drivers were higher asset utilisation in NCB, DCB and NT, and a company-wide cost-optimisation drive with 70% of identified initiatives implemented.

The Q1 FY2027 acceleration — and its quality. Q1 FY2027 EBITDA rose 79% YoY to ₹385 Cr and PAT 260% to ₹155 Cr. This must be read carefully. Management disclosed that combined inventory and foreign-exchange gains contributed approximately ₹50–60 Cr to the quarter, and that overall volumes declined about 12%. Stripping ₹55 Cr of one-time-ish gains from ₹385 Cr leaves roughly ₹330 Cr — still up sharply YoY, but the quarter is a mix-and-inventory story, not a volume story. The critical monitorable is whether the run-rate holds when low-cost inventory is exhausted.

The cash-flow problem. This is the most under-appreciated feature of the financials. Free cash flow has been negative in every one of the last five years, cumulatively about ₹-1,233 Cr. FY2026 was the worst year since FY2022 on both FCF (₹-346 Cr) and cash conversion (CFO at 67% of operating profit versus 123–132% in FY2023–FY2025), because working capital absorbed cash as debtor days jumped from 39 to 62. Borrowings rose ₹1,118 Cr in FY2026 alone. The company has funded five years of growth from the balance sheet, and the balance sheet is now visibly stretched.

The tax anomaly. The effective tax rate has been negative for three consecutive years (-5%, -8%, -15%). This reflects deferred tax credits and location-based incentives (SEZ and concessional-rate regimes), plus favourable tax orders that generated ₹29 Cr of exceptional income in Q2 FY2026. Screener flags "tax rate seems low" as an automated warning. The sustainability of a negative effective tax rate is a genuine forward risk to reported EPS and is not something a valuation should extrapolate.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

End-use Application Details

End-use applicationQ1 FY2027 revenue share (%)

Energy and additives

38

Agrochemicals and fertilizers

18

Dyes, pigments and printing inks

15

Pharmaceuticals

14

Polymer and additives

11

Segment Revenue

Product groupFY2025FY2026Q1 FY2027Commentary

NCB

85%

85%

85%

Consistently full; the profit engine

DCB

85%

85%

85%

Debottlenecking from 120 kTPA to 140 kTPA underway on PDCB/downstream demand

Hydrogenation

85%

85%

85%

Full utilisation

Methylation (fuel additives)

High

High

High

Capacity raised 200→290→360 kTPA

NT / Ethylation

65–85%

65–85%

65–85%

Improvement expected as PEDA downstream integration and MEA demand build

PDA

Weak ("red")

Weak ("red")

Improving ("yellow")

Subdued US demand plus Chinese competition; the portfolio's problem child

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations, net of GST (INR Cr)

6,0866,6196,3717,2718,286

Operating expenses (INR Cr)

4,3655,5305,3936,2717,119

EBITDA / operating profit (INR Cr)

1,7201,0899781,0001,167

Other income (INR Cr)

1171612

Depreciation and amortisation (INR Cr)

246310378434474

EBIT (INR Cr)

1,474779600566693

Finance cost (INR Cr)

102168211275340

Profit before tax (INR Cr)

1,372611395307365

Net profit (INR Cr)

1,186545416331419

EPS basic (INR)

32.7115.0411.499.1311.56

Effective tax rate (%)

1411-5-8-15

Dividend payout (% of PAT)

11179119

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

EBITDA margin (%)

28.316.515.313.814.1

EBIT margin (%)

24.211.89.47.88.4

Pre-tax margin (%)

22.59.26.24.24.4

Net margin (%)

19.58.26.54.65.1

Financial Analysis

MeasureValue (%)

Revenue CAGR FY2022–FY2026 (4 years, on the reported series)

8.0

Revenue CAGR FY2023–FY2026 (3 years, post-demerger, clean basis)

7.8

Revenue growth FY2026 vs FY2025, net of GST

14.0

Revenue growth FY2026 vs FY2025, gross (company headline)

12.0

Trailing-twelve-month revenue growth to Q1 FY2027

27.0

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Equity share capital (INR Cr)

181181181181181

Reserves and surplus (INR Cr)

4,3354,7395,1095,4245,774

Total shareholders equity (INR Cr)

4,5164,9205,2905,6055,955

Total borrowings (INR Cr)

2,5872,9073,6233,8484,966

Other liabilities (INR Cr)

7487541,2031,6612,378

Total assets / liabilities (INR Cr)

7,8518,58110,11511,11413,299

Net fixed assets (INR Cr)

3,5954,8615,6496,3776,556

Capital work in progress (INR Cr)

1,3461,0961,2291,4542,030

Investments (INR Cr)

28172348132

Other assets incl. working capital (INR Cr)

2,8822,6073,2143,2354,581

Book value per share (INR)

124136146155164

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Cash from operating activities (INR Cr)

5191,3191,2101,242775

Cash used in investing activities (INR Cr)

-1,169-1,330-1,369-1,398-1,141

Cash from financing activities (INR Cr)

41238420-73745

Net change in cash (INR Cr)

-23927261-229379

Free cash flow (INR Cr)

-646-8-96-137-346

Operating cash flow as % of operating profit

4412913212367

Capital expenditure, company-stated (INR Cr)

———1,3001,125

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

Return on equity, on average equity (%)

29.611.68.16.17.2

Return on assets, on average assets (%)

15.36.64.53.13.4

Return on capital employed, as reported (%)

2210767

Total debt to equity (x)

0.570.590.680.690.83

Interest coverage, EBIT over finance cost (x)

14.54.62.82.12.0

Asset turnover, revenue over average assets (x)

0.790.810.680.690.68

Debtor days

6552493962

Inventory days

143115121126118

Payable days

532476107126

Cash conversion cycle (days)

155143945854

Financial Ratios (x)

MetricQ1 FY2026Q4 FY2026Q1 FY2027

Interest service coverage ratio (x)

1.742.023.34

Debt service coverage ratio (x)

0.641.542.33

Net debt to equity (x)

0.660.720.80

Current ratio (x)

0.79—0.82

Total debt to total assets (x)

0.34—0.38

Debtors turnover (x)

8.23—7.12

Inventory turnover (x)

3.84—3.63

Revenue by Region (%)

MetricQ1 FY2027

Export share of revenue (%)

59

Domestic share of revenue (%)

41

Countries of operation

60

Application Details

ApplicationDomestic share (%)Export share (%)

Agrochemicals and fertilizers

5842

Energy and additives

694

Pharmaceuticals

8119

Valuation Snapshot

MetricValue

Share price (13 August 2026)

₹532

52-week high / low

₹541 / ₹338

Market capitalisation

₹19,306 Cr

Face value

₹5.00

Share Price History

PeriodShare price CAGR (%)

1 year

39

3 years

5

5 years

-9

10 years

15

Capital Markets

MetricAarti Industries

Trailing P/E (x)

37.0

Price / book (x)

3.23

Book value per share (INR)

164

Dividend yield (%)

0.19

Market cap / TTM sales (x)

2.14

Enterprise value / FY2026 EBITDA (x, derived using ~₹4,288 Cr net debt)

~20.2

Peer Comparison

CompanyP/E at that observation (x)

Aarti Industries

57.3

Navin Fluorine International

71.4

BASF India

49.5

Vinati Organics

41.3

Deepak Nitrite

39.8

Atul Limited

32.1

Source Details

SourceCoverageConsensus rating12-month target (INR)

Stockanalysis.com

23 analysts

Buy

534.09

Stockopedia

Consensus

Buy

536.65

Alpha Spread (buy- and sell-side pool)

Consensus

—

544.73 (low 369.66 / high 653.10)

Trendlyne

5 recent reports, 3 sources

—504

TipRanks

1 analyst

Hold

414 (stale observation)

Returns & Leverage Ratios (%)

MetricFY2022FY2023FY2024FY2025FY2026

Dividend payout ratio (%)

11179119

Credit Ratings

AgencyInstrumentRatingOutlookDate

Crisil Ratings

Long-term bank facilities and long-term borrowing programme

Crisil AA

Negative

11 Sep 2025 (reaffirmed 29 Oct 2025)

Crisil Ratings

Short-term bank facilities and commercial paper

Crisil A1+

—

11 Sep 2025

India Ratings (Ind-Ra)

Bank loan facilities and debt instruments

Rated; outlook previously revised to Negative from Stable

Negative

—

Facility Type Details

Facility typeApproximate totalRating

Fund-based facilities

1,141

Crisil AA/Negative

Rupee term loans and term loans

362

Crisil AA/Negative

Proposed long-term bank loan facility

283

Crisil AA/Negative

Non-fund-based limits

784

Crisil A1+

Working capital demand loan

230

Crisil A1+

Total rated facilities

~2800

—

Analyst Conclusions

Management guidance

Guidance itemValueHorizon
EBITDA₹1,800–2,200 CrFY2028
Debt / EBITDABelow 2.5xOngoing
Return on capital employedAbove 15%Ongoing
Capital expenditure₹700–800 Cr (₹180 Cr deployed in Q1)FY2027
Capex intensity"Should ease next year as major expansion programmes near completion"FY2028
New fuel-additive products5–10 by end-FY2027; 25–30 by FY2028FY2027–28
Augene JV commissioningQ2 FY2027; profit contribution within 2–4 quartersFY2027
Re Aarti commissioningH2 FY2027FY2027
Zone IVPhased commissioning FY2027; ramp-up FY2028–FY2029FY2027–29

Management's stated posture is "cautiously optimistic," citing stable demand, emerging recoveries, upcoming capacity expansions, customer qualifications and operational excellence, while flagging West Asia feedstock risk.

Consensus expectations

Consensus (23 analysts) is Buy with a 12-month target of approximately ₹534, implying roughly flat-to-7% upside from ₹532. Consensus next-year EPS is ₹14.36, versus FY2026 actual of ₹11.56 — implying about 24% EPS growth. Third-party model projections put three-year revenue CAGR at roughly 16% and net income CAGR at roughly 28%.

The consensus is doing something specific and worth naming: it is forecasting strong earnings growth while assigning almost no further multiple expansion. After a 39% one-year run, the market has already paid for the recovery and is waiting for proof.

Bull case

  1. The EBITDA bridge is arithmetically sound and two of its three legs are already substantially delivered. Cost optimisation (₹150–200 Cr) is described as largely completed with 70% of initiatives implemented; volume and margin ramp-up (₹350–550 Cr) is "on track as planned." Only the capex-led leg (₹300–450 Cr) carries full execution risk. If the first two legs alone deliver at midpoint, FY2028 EBITDA reaches roughly ₹1,700 Cr without any new plant contributing — within touching distance of the guidance floor.

  2. Two structural, externally-driven margin tailwinds are already in force and are not in the FY2026 base. China's April 2026 export VAT-rebate withdrawal lifted NCB-chain pricing 7–10% within days on the company's largest chain, and US tariffs fell from >50% to ~18%+ on a US export book that is 65–80% MMA and PDCB. Neither required capital or execution from Aarti. Q4 FY2026 EBITDA margin of 15.56% versus 13.75% a year earlier, and Q1 FY2027 at approximately 16%, show the pass-through beginning.

  3. Capex intensity is falling for the first time in six years, which mechanically turns free cash flow. FY2027 capex guidance of ₹700–800 Cr against FY2026 actual of ~₹1,125 Cr is a ~₹350 Cr reduction. Applied to FY2026's operating cash flow of ₹775 Cr — itself depressed by a one-off working-capital build — free cash flow turns positive in FY2027 on any reasonable CFO recovery toward the ₹1,200+ Cr achieved in FY2023–FY2025. Positive FCF resolves the leverage concern, resolves the Crisil Negative outlook, and re-rates the equity independently of the EBITDA target.

Bear case

  1. The recovery quarter is substantially not operational. Q1 FY2027 delivered 79% EBITDA growth on 12% lower volumes, with management conceding ₹50–60 Cr of inventory and forex gains — roughly 14–16% of reported EBITDA. Excluding those, EBITDA is approximately ₹330 Cr, an annualised ₹1,320 Cr against a target of ₹1,800–2,200 Cr. When low-cost inventory is exhausted and the rupee stabilises, the gains reverse. The market has re-rated the stock 39% on a quarter whose quality management itself qualified.

  2. The execution leg is already failing, in real time. Within a single quarter, Zone IV slipped two quarters, the chlorotoluene chain slipped 3–6 months, and Re Aarti slipped three months — the exact projects underpinning the ₹300–450 Cr capex-led EBITDA contribution. These are labour-constraint and war-related delays, meaning they are not within management's control and may extend. Zone IV's ₹1,600–1,800 Cr is already largely spent; the capital is sunk whether or not the EBITDA arrives on schedule.

  3. The balance sheet cannot absorb a second disappointment. Total debt rose ₹1,118 Cr in FY2026 to ₹4,966 Cr; net debt/EBITDA is roughly 3.7x against a 2.5x self-imposed ceiling; interest coverage is 2.0x; the current ratio is 0.82x with payable days already stretched to 126; free cash flow has been negative for five consecutive years; and Crisil's outlook has been Negative since September 2025 with an explicit ROCE condition that has not been met in three years. If FY2028 EBITDA lands at ₹1,500 Cr rather than ₹2,000 Cr, leverage stays near 3x, the rating comes under pressure, and a stock trading at 37× trailing earnings and 3.2× book has no valuation support to fall back on.

Catalysts and monitorables — next twelve months

#Catalyst / monitorableWhy it mattersExpected timing
1Q2 FY2027 EBITDA excluding inventory/forex gainsThe single cleanest test of earnings qualityNov 2026
2Volume trajectory — does the 12% Q1 decline reverse?Distinguishes a mix story from a demand storyNov 2026
3Augene (Superform JV) commissioning and rampFirst of the capex-led EBITDA contributions; guided to contribute within 2–4 quartersQ2 FY2027
4MPP commissioning and product qualification (PEDA, Coral)Converts sunk Zone IV capital into revenueQ2 FY2027 onward
5Fuel-additive utilisation at 360 kTPAManagement expects high utilisation in Q2 FY2027; the largest single volume driverNov 2026
6Free cash flow turning positiveEnds five years of balance-sheet funding; the key to the ratingFY2027 full year
7Crisil outlook resolution — Negative to Stable, or a downgrade to AA-Directly conditioned on double-digit ROCENext review cycle
8Any further Zone IV or chlorotoluene slippageThe ₹300–450 Cr EBITDA legQuarterly
9Durability of the China VAT-rebate effect on NCB pricingThe largest exogenous margin driverOngoing
10Re Aarti commissioningCircular-economy platform; already delayed onceH2 FY2027
11Effective tax rate normalisationThree years of negative ETR flatters EPSFY2027–28
12Working capital: debtor days back from 62 toward 39The proximate cause of FY2026's cash-flow deteriorationQuarterly
13FII re-entry — holding is 7.00% vs 10.93% two years ago; Singapore/Hong Kong roadshow held 11–14 August 2026Marginal-buyer dynamicsSep 2026 shareholding
14Further promoter reclassificationHolding has fallen 12 points in nine yearsOngoing
15China subsidiary establishmentSourcing and market access in a market >45% of global chemicalsFY2027
16Absolute Scope 1+2 emissions trajectoryCurrently moving away from a 54.6% absolute reduction targetAnnual BRSR

Analyst verdict

Aarti Industries is a genuinely good business currently earning bad returns, and the entire investment question is whether the gap closes in the next twenty-four months.

The quality is real. Global leadership in the NCB chain is corroborated by two independent rating agencies, not merely asserted. Core chains run above 85% utilisation. The ESG credentials — EcoVadis Platinum at 87/100, top 1% globally, and S&P Global CSA at 78, top 2% of chemicals — are commercially load-bearing with European and Japanese buyers, not decorative. The Middle East reallocation from 15% to 2% of revenue inside one quarter demonstrated operational agility that few peers could match. And two long-term contracts, including US$150m to 2030 requiring no incremental capex, provide the revenue visibility that a leveraged manufacturer most needs.

The returns are not real, yet. Five consecutive years of negative free cash flow. ROCE of 6–7% against a >15% target. Net debt/EBITDA near 3.7x against a 2.5x ceiling. Interest coverage at 2.0x. A net margin of 5.1% when Vinati earns 21% on 28% of the revenue. Crisil has carried a Negative outlook since September 2025 conditioned on a ROCE improvement that has not arrived.

The FY2026 recovery is genuine but modest; the Q1 FY2027 acceleration is genuine but flattered — ₹50–60 Cr of inventory and forex gain, on 12% lower volumes.

At 37× trailing earnings and 3.2× book, after a 39% twelve-month run, the market has already paid for successful execution of the FY2028 bridge. Analyst targets clustering at ₹504–545 against a ₹532 price confirm it: consensus sees the story and sees no remaining discount.

The verdict is that this is a well-run company at an inflection whose equity is priced as though the inflection has already succeeded. The asymmetry currently favours waiting for two clean, non-inventory-assisted quarters over paying today's multiple for a bridge whose third leg has already slipped twice.


END OF DOSSIER

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleCategoryFY2025 total remuneration (INR Cr)Shareholding (%)

Rajendra V. Gogri

Chairman & Managing Director

Executive / Promoter

4.701.91

Rashesh C. Gogri

Vice Chairman & Managing Director

Executive / Promoter

4.704.09

Renil R. Gogri

Executive Director & Vice-Chairman

Executive / Promoter

1.943.08

Suyog Kotecha

CEO & Executive Director

Executive / Professional

3.550.0003

Manoj M. Chheda

Executive Director

Executive

2.260.84

Ajay Kumar Gupta

Executive Director & Chief Manufacturing Officer

Executive

3.620.0009

Hetal Gogri Gala

Director

Non-Executive / Promoter group

——

Belur Krishnamurthy Sethuram

Director

Independent

——

Rupa Devi Singh

Director

Independent

——

Shekhar Khanolkar

Director

Independent

——

Prof. Aniruddha B. Pandit

Director

Independent

——

Lalitkumar Naik

Director

Independent

——

Ashok Kumar Barat

Director

Independent

——

Nikhil J. Bhatia

Director

Independent

——

Chandrakant V. Gogri

Chairman Emeritus

Founder, non-board honorific

——

Board & Management Changes

DateChange

17 June 2024

Suyog Kotecha appointed CEO & Executive Director — the first professional chief executive, with recognised chemical-industry leadership experience

2025

Hetal Gogri Gala joins the board as Non-Executive Director

30 July 2026

Risk Management Committee renamed ESG Committee; Nikhil J. Bhatia inducted

3 August 2026

Reclassification application filed to move Ratanben Premji Gogri (13,77,330 shares) from Promoter Group to Public

~August 2026

Smt. Ketki D. Visariya re-appointed Cost Auditor for FY2026-27

Shareholding Trend

Holder categoryMar 2024Mar 2025Mar 2026Jun 2026

Promoters (%)

43.4342.2442.0941.82

Foreign institutional investors (%)

10.936.297.387.00

Domestic institutional investors (%)

17.2419.9620.1221.11

Government (%)

0.030.010.010.01

Public and others (%)

28.3831.4830.3930.08

Number of shareholders

377,953439,227384,210370,868

Competitive Landscape

Key Competitors

CompetitorPrimary overlap with AIL

Deepak Nitrite

Direct and severe — phenol/acetone, nitro-aromatics, fuel and rubber intermediates; the closest structural analogue in India

Atul Ltd

Aromatics, life-science chemicals, performance chemicals; overlaps in dyes/pigment and agro intermediates

Vinati Organics

IBB and ATBS; overlaps in aromatic speciality intermediates, though a narrower, higher-margin portfolio

Navin Fluorine International

Fluorination chemistry, CDMO; direct competition in AIL's fluoro products and CDMO ambitions

SRF Ltd

Speciality chemicals and fluorochemicals; agro and pharma intermediates

Clean Science and Technology

Catalytic process chemistry; performance and pharma intermediates

PI Industries

Agrochemical CSM/CDMO; competes for the same global agro-innovator contracts

Anupam Rasayan

Custom synthesis of agro and pharma intermediates

Laxmi Organic Industries

Acetyl and speciality intermediates

NOCIL

Rubber chemicals; overlaps in aniline-derived chemistry

Sudarshan Chemical Industries

Pigments — a customer-adjacent competitor in the dyes/pigments chain

Acutaas Chemicals (formerly Ami Organics)

Pharma intermediates and speciality chemicals

Aether Industries

Advanced intermediates, CDMO

Fine Organic Industries / Galaxy Surfactants

Adjacent oleochemical and surfactant specialities; peer-group comparators rather than direct competitors

Peer Comparison FY2026

MetricAarti IndustriesVinati OrganicsNavin Fluorine Intl.Deepak Nitrite

FY2026 revenue (INR Cr)

8,2862,2813,314—

FY2026 revenue growth (%)

14.0-0.541.08.1

FY2026 net profit (INR Cr)

419488664—

FY2026 net profit growth (%)

26.617.5130.0—

FY2026 net margin (%)

5.121.420.0—

FY2026 EBITDA margin (%)

14.1———

Return on equity, latest year (%)

7.2———

Company Snapshot

6,000

Employees

$2,200M

Market Cap

1984

Founded

Gujarat, India

Headquarters

SWOT Analysis

Strengths

  • Global leadership in the NCB chain, corroborated independently by India Ratings ("leading market position globally in benzene derivatives space") and Crisil ("market leadership"), not merely self-asserted.
  • NCB, DCB and hydrogenation utilisation above 85% across FY2025, FY2026 and Q1 FY2027 — the core chains are demand-constrained by capacity, not by orders.
  • Contracted revenue visibility: a US$150m agrochemical contract to 31 March 2030 requiring no incremental capex, plus a 15-year integrated arrangement with a global chemical major backed by a ₹200–250 Cr Dahej SEZ investment.
  • Best-in-class ESG credentials: EcoVadis Platinum at 87/100 (top 1% globally, June 2026), S&P Global CSA 78 (top 2% of chemicals), CDP Climate Leadership Band A, Water A-, Supplier Engagement A — a commercial gating advantage with European and Japanese buyers.
  • Demonstrated operational agility: Middle East revenue exposure reduced from ~15% to 2% within a single quarter while sustaining 79% YoY EBITDA growth.
  • Full backward integration, including 175,000 TPA captive chlorination and captive sulphuric acid, cited by India Ratings as a business-profile support.
  • Scale and diversification: 100+ products, 1,100+ customers, 60 countries, 16 plants, five end-markets none of which exceeds 38% of revenue.

Weaknesses

  • Return on capital employed of 6–7% for three consecutive years (FY2024, FY2025, FY2026) against a stated >15% target — a 800–900 basis point gap.
  • Net margin of 5.1% in FY2026 versus roughly 21% at Vinati Organics and 20% at Navin Fluorine, despite being 2.5–3.6× larger by revenue.
  • Negative free cash flow in each of the last five years, cumulatively about ₹-1,233 Cr, worst in FY2026 at ₹-346 Cr.
  • Leverage above the company's own ceiling: total debt ₹4,966 Cr at FY2026 (up ₹1,118 Cr in one year), net debt/equity 0.80x at Q1 FY2027, derived net debt/EBITDA of roughly 3.7x versus a stated <2.5x limit.
  • Interest coverage of 2.0x in FY2026, down from 14.5x in FY2022 and 4.6x in FY2023.
  • Current ratio of 0.82x — current liabilities exceed current assets; payable days extended from 24 (FY2023) to 126 (FY2026), a working-capital strategy with limited further headroom.
  • Persistent PDA/MPDA underperformance — utilisation in "red" through FY2025 and FY2026, only improving to "yellow" in Q1 FY2027.
  • A negative effective tax rate for three consecutive years (-5%, -8%, -15%) flatters reported EPS and is not a durable earnings source.

Opportunities

  • China's April 2026 export VAT-rebate withdrawal on major NCB-chain products, which lifted chain pricing 7–10% within days — a structural, ongoing margin tailwind on the company's largest chain.
  • US tariff reduction from >50% to ~18%+, directly benefiting the 65–80% of US exports represented by MMA and PDCB.
  • Fuel-additive capacity now at 360 kTPA (from 200 kTPA two years ago), into a market management sizes "in the millions of tons," with 25–30 new products targeted by FY2028.
  • The capex-led EBITDA leg of ₹300–450 Cr from MPP, Zone IV, Augene and Re Aarti — all scheduled to commission in FY2027.
  • Augene (Superform JV) expected to contribute meaningfully to profit within 2–4 quarters of Q2 FY2027 commissioning, with management noting end-application tailwinds that may accelerate utilisation.
  • CDMO and China+1 reallocation, supported by the pilot-to-MPP scale-up ecosystem and a planned China subsidiary in a market representing >45% of global chemical demand.
  • Capex intensity falling from ~₹1,125 Cr (FY2026) to ₹700–800 Cr (FY2027) — the first structural opportunity for free cash flow to turn positive in six years.

Threats

  • Chinese pricing power. The company's single largest FY2027 margin tailwind was a Chinese policy decision, reversible by the same mechanism. MPDA and fluoro products are already being competed away.
  • Execution slippage is already occurring: Zone IV delayed two quarters, chlorotoluene 3–6 months, Re Aarti three months — all on the ₹300–450 Cr EBITDA leg.
  • Contract termination precedent. A long-term supply contract was mutually terminated in January 2022, materially resetting the earnings base. Both current material contracts are with unnamed counterparties whose concentration cannot be independently assessed.
  • Crisil's Negative outlook (11 September 2025), with the agency explicitly conditioning the rating on capex ramp-up lifting ROCE to double digits — which has not happened.
  • Q1 FY2027 earnings quality: approximately ₹50–60 Cr of the ₹385 Cr EBITDA came from inventory and forex gains, while volumes fell about 12%. If input costs normalise, the inventory benefit reverses.
  • Raw-material inflation with a pass-through lag — management stated raw material prices are unlikely to return to January–February levels amid high input inflation.
  • Single-region asset concentration in Gujarat and Maharashtra across all 16 plants.
  • Competitors scaling fuel-additive capacity into the same demand outlook AIL is expanding against — the one clearly attractive niche is attracting entrants.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Feb 2025Q3 FY2025 results: net revenue ₹1,843 Cr, EBITDA ₹231 Cr, PAT ₹46 CrTrough-zone quarter; PAT down sharply on interest and depreciation
6 Feb 2025India Ratings rating action; agency cites leading global position in benzene derivatives and multiple long-term contracts, but notes price pressure through 9M FY2025Credit view: business strong, cycle weak
7 Mar 2025Crisil reaffirms Crisil AA/Stable / Crisil A1+; flags that timely ramp-up of past and current capex, lifting ROCE to double digits, remains a monitorableThe explicit pre-condition for the rating
8 May 2025Q4 and FY2025 results: FY2025 net revenue ₹7,271 Cr, EBITDA ₹1,000 Cr, PAT ₹331 Cr; dividend ₹1.00/share declaredEarnings trough confirmed: PAT down 20% YoY
May 2025Q4 FY2025 earnings call and investor presentation filed—
Jul 2025AGM presentation filed—
Aug 2025Q1 FY2026 results: net revenue ₹1,675 Cr, EBITDA ₹212 Cr, PAT ₹43 Cr; revenue down ~16% QoQWeakest quarter of the cycle
11 Sep 2025Crisil revises outlook to Negative from Stable, reaffirming Crisil AA / Crisil A1+The formal credit warning; the single most important negative event of the period
29 Oct 2025Crisil Credit Bulletin: bank-wise facility details updated per RBI requirement; ~₹1,656 Cr of long-term facilities at Crisil AA/Negative and ~₹1,014 Cr short-term at Crisil A1+ across 12 lendersReveals the bank group: SBI, IDBI, Kotak, HDFC, Standard Chartered, Axis, IndusInd, Bank of Baroda, DBS, HSBC, Citibank
6 Nov 2025Q2 FY2026 results: net revenue ₹2,100 Cr (gross ₹2,250 Cr, +26% YoY), EBITDA ₹291 Cr (+44%), PAT ₹106 Cr (+102%); includes exceptional income of ₹29 Cr from favourable tax orders; energy volumes +118% YoYThe inflection quarter
7 Nov 2025Share price rises ~5% to ₹410.20 on the resultMarket re-rating begins
Nov 2025Management flags margins still pressured by elevated input prices and US trade restrictions affecting dyes and polymers; FY2026 capex signalled below ₹1,000 CrGuidance later revised upward
Jan 2026Q3 FY2026 pre-results: brokerages forecast AIL among the sector's stronger performersSentiment turn
Feb 2026Q3 FY2026 results: net revenue ₹2,318 Cr (gross ₹2,492 Cr, +22% YoY), EBITDA ₹323 Cr (+37%), PAT ₹133 Cr (+25%); resumption of US volumes for MMA and PDCBThird consecutive improving quarter
Feb 2026S&P Global Corporate Sustainability Assessment 2025 score of 78 — top 2% of assessed chemical companies globallyESG credential with commercial value
Feb 2026FY2026 capex guidance raised to ~₹1,100 Cr from ₹1,000 Cr for MMA expansion and PEDA; Zone IV total capex framed at ₹1,600–1,800 Cr; MPP commissioning expected Q4 FY2026Capex discipline slipping, for growth reasons
Feb 2026Management notes US tariff reduction from >50% to ~18%+, expected to benefit all playersPolicy tailwind
5 Feb 2026India Ratings rating update issued–
12 Mar 2026US$150 million multi-year agrochemical supply contract announced under Reg. 30, running to 31 March 2030, requiring no incremental capex; share price ₹438.40 (+1.92%) on the dayCapex-free revenue visibility
April 2026China removes export VAT rebate on major NCB-chain products; NCB chain pricing rises 7–10% within daysExternal structural tailwind
6 Apr 2026SEBI compliance certificate submitted for Q4 FY2026Routine
8 Apr 2026Second 100-day "Saksham Niveshak" unclaimed-dividend awareness campaign launchedShareholder-service initiative
11 Apr 2026Special window reopened for re-lodgement of physical share transfersRoutine
13 Apr 2026122 equity shares allotted under Performance Stock Option Plan 2022Routine
15 Apr 2026₹51.76 Cr block trade executed on NSECounterparties not disclosed
4 May 2026Q4 and FY2026 results: Q4 net revenue ₹2,205 Cr (gross ₹2,422 Cr, +9% YoY), Q4 EBITDA ₹343 Cr (+29%), Q4 PAT ₹137 Cr (+43%), Q4 EBITDA margin 15.56% vs 13.75%. FY2026: gross revenue ₹9,018 Cr (+12%), EBITDA ₹1,172 Cr (+15%), PAT ₹419 Cr (+27%). Dividend ₹1.00/share (20%) recommendedThe recovery year confirmed
4 May 20262026 Gallup Exceptional Workplace Award announced alongside resultsCulture credential
5 May 2026Q4 FY2026 earnings conference call: FY2027 capex guidance ₹700–800 Cr; 2,80,700 stock options granted under PSOP 2022Capex intensity easing
Q4 FY2026 / May 2026Material amendment to exclusive long-term supply agreement with a leading global chemical company: ₹200–250 Cr backward integration at Dahej SEZ over a 15-year periodSecond strategic contract of the year
4 Jun 2026EcoVadis Platinum rating achieved, 87/100 — top 1% of companies globally, upgraded from GoldBest-in-class ESG credential
23 Jun 2026Sale of 100% of Shanti Intermediates Pvt Ltd for ₹150.18 lakh by Aarti Corporate Services Ltd to non-promoter buyers; entity had negative net worth of ₹147.80 lakhImmaterial cleanup
Q1 FY2027West Asia conflict: Middle East revenue exposure cut from ~15% to 2%; volumes redirected to US, Europe, Africa and IndiaCrisis management executed within one quarter
Jul 2026Fuel-additive capacity expansion completed: 290 kTPA → 360 kTPALargest volume driver upsized
Jul 2026Zone IV and chlorotoluene projects delayed 3–6 months on labour constraints and war-related issues; Re Aarti delayed ~3 months to H2 FY2027Execution slippage on the ₹300–450 Cr EBITDA leg
30 Jul 2026Risk Management Committee renamed ESG Committee; Nikhil J. Bhatia inductedGovernance elevation of sustainability
31 Jul 2026Q1 FY2027 results: gross revenue ₹2,627 Cr (+41% YoY), net revenue ₹2,387 Cr (+42%), EBITDA ₹385 Cr (+79% YoY, +13% QoQ), PBT ₹180 Cr (+329%), PAT ₹155 Cr (+260%), basic EPS ₹4.27, capex ₹180 Cr. Volumes down ~12%; inventory and forex gains ~₹50–60 Cr. ISCR 3.34x, DSCR 2.33x, net debt/equity 0.80xStrongest reported quarter in years, of mixed quality
31 Jul 2026Share price +2.67% to ₹493 following the presentation, approaching the 52-week high—
1 Aug 2026Newspaper publication of unaudited financial resultsRoutine
3 Aug 2026Reclassification application filed for Ratanben Premji Gogri (13,77,330 shares), promoter group to publicContinued promoter dilution
6 Aug 2026Intimation of investor meets in Singapore and Hong Kong, 11–14 August 2026Active courting of the FII base that exited in FY2025
7 Aug 2026Q1 FY2027 earnings call transcript filed—
~Aug 2026Smt. Ketki D. Visariya re-appointed Cost Auditor for FY2026-27Routine

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Income Statement: Revenue & Gross Profit: Revenue from operations, net of GST rose from INR 60,860 Mn in FY2022 to INR 82,860 Mn in FY2026.
Aarti Industries — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations, net of GST60,86066,19063,71072,71082,860

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.